MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1312
+0.0107
+8.88%
After Hours: 0.1290 -0.0022 -1.68% 16:37 10/22 EDT
OPEN
0.1260
PREV CLOSE
0.1205
HIGH
0.1356
LOW
0.1230
VOLUME
8.94M
TURNOVER
--
52 WEEK HIGH
0.5450
52 WEEK LOW
0.1128
MARKET CAP
15.32M
P/E (TTM)
-0.3483
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 1d ago
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 2d ago
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)
Benzinga · 6d ago
Titan Pharmaceuticals issues strategic and corporate update
Titan Pharmaceuticals (TTNP) announces an update on its strategic restructuring.It plans to restructure the Company to focus on ProNeura based product development, specifically a kappa opioid receptor agonist and nalmefene.It plans to
Seekingalpha · 10/15 13:34
Titan Pharmaceuticals Provides Strategic & Corporate Update
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced a strategic restructuring designed to position it
Benzinga · 10/15 12:13
Titan Pharma prices $2.7M direct offering
Titan Pharmaceuticals (TTNP) slips 4.7% in premarket after announcement of a share purchase agreement with certain accredited institutional investors to purchase ~19.4M shares in a registered direct offering at $0.14/share, with net
Seekingalpha · 09/24 13:08
Titan Pharmaceuticals Announces Pricing Of $2.7M Direct Offering At $0.14/Share
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ --Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced it has
Benzinga · 09/24 13:02
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a share purchase agreement with certain accredited institutional investors to purchase 19,440,000 shares of its common stock in a registered direct offering at a purchase price of $0.14 per share.
PR Newswire · 09/24 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TTNP. Analyze the recent business situations of Titan Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTNP stock price target is 0.8000 with a high estimate of 0.8000 and a low estimate of 0.8000.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 2.69M
% Owned: 2.30%
Shares Outstanding: 116.76M
TypeInstitutionsShares
Increased
5
219.81K
New
14
-587.66K
Decreased
3
378.42K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Marc Rubin
President/Chief Operating Officer/Chief Scientific Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Lead Director
Seghi Recli
Independent Director
James McNab
Independent Director
Scott Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.